Where to Get Zepbound Cheap in 2026: The 7 Options That Actually Work

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound costs $1,059 per month at retail without insurance, but seven distinct pathways can reduce this to $25 to $299 monthly depending on your insurance, income, and clinical situation
• The Lilly savings card reduces copays to $25 monthly for commercially insured patients, but excludes anyone on Medicare, Medicaid, or government plans (roughly 40% of potential users)
• Compounded tirzepatide from licensed telehealth platforms costs $179 to $299 monthly with no insurance required, making it the most accessible option for patients whose insurance denies coverage
• Costco consistently offers the lowest cash price among major retail pharmacies at $989 to $1,015 per month, compared to $1,059 to $1,150 at CVS and Walgreens

Direct answer (40-60 words)

The cheapest verified Zepbound access in 2026 comes from seven sources: the Lilly savings card ($25/month for eligible commercial insurance), Lilly Cares patient assistance (free for low-income uninsured), compounded tirzepatide telehealth ($179-299/month), Costco cash pricing ($989/month), GoodRx coupons ($920-980/month), manufacturer copay maximizer programs, and clinical trial enrollment.

Table of contents

1. The pricing reality most articles ignore
2. Option 1: The Lilly savings card (who qualifies, who doesn't)
3. Option 2: Lilly Cares Foundation patient assistance program
4. Option 3: Compounded tirzepatide through telehealth platforms
5. Option 4: Costco and Sam's Club membership pricing
6. Option 5: GoodRx and discount card programs
7. Option 6: Copay accumulator workarounds
8. Option 7: Clinical trial participation
9. The three-question decision tree
10. What most coverage guides get wrong about "cheap"
11. Real cost comparison across all seven pathways
12. FAQ

The pricing reality most articles ignore

Most "how to save on Zepbound" content recycles the same three tips: use the savings card, try GoodRx, ask about patient assistance. This creates a dangerous information gap because those three options exclude the majority of patients who search for cheaper Zepbound.

Here's the distribution problem: approximately 63 million Americans are enrolled in Medicare (Cubanski et al., KFF 2025), 85 million in Medicaid (CMS 2026), and 9 million in other government programs. That's 157 million people, roughly 47% of the U.S. population, who cannot use manufacturer savings cards due to federal anti-kickback statutes.

The second gap: insurance coverage for weight loss medications remains inconsistent. A 2025 analysis of employer health plans found that only 41% covered GLP-1 medications for obesity, and of those, 68% required prior authorization with a median approval time of 9 business days (Peterson-KFF Health System Tracker 2025).

The result is a two-tier system where "cheap Zepbound" means completely different things depending on your insurance category. For commercially insured patients with formulary coverage, cheap means $25 to $75 monthly. For Medicare patients, cheap means $900+ monthly or switching to a compounded alternative. For uninsured patients, cheap means choosing between $989 cash price at Costco or $179 to $299 for compounded tirzepatide.

This article maps all seven pathways with specific eligibility gates, not aspirational advice.

Option 1: The Lilly savings card (who qualifies, who doesn't)

The Lilly savings card is the most advertised option and works exactly as promised for the subset of patients who qualify.

Eligibility requirements:

• Commercial insurance that covers Zepbound (any tier, any copay amount)
• Prescription written for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidity
• Not enrolled in Medicare, Medicare Advantage, Medicaid, TRICARE, VA, or any federal or state healthcare program
• U.S. resident, 18 years or older

What it provides:

• Reduces copay to as low as $25 per month
• Maximum savings of $563 per prescription
• Valid for up to 13 fills per calendar year
• Resets January 1 each year

The math on maximum savings: If your insurance-negotiated price is $1,059 and your plan's coinsurance is 30% ($318), the card reduces your out-of-pocket to $25. The card covers $293 of your copay. If your copay is $600, you'd pay $37 after the card (the $563 maximum applies).

Who this excludes: The 47% of Americans on government insurance cannot use this card. Period. Federal law prohibits manufacturers from subsidizing copays for government beneficiaries because it's considered an inducement that could influence prescribing (42 U.S.C. 1320a-7b).

Additionally, patients whose insurance doesn't cover Zepbound at all cannot use the card. The card reduces an existing copay; it doesn't create coverage where none exists.

How to get it: Download from LillyDirect.com or ZepboundHCP.com. Bring the digital or printed card to your pharmacy alongside your insurance card. The pharmacist processes insurance first, then applies the savings card to the remaining copay.

Pattern recognition from FormBlends clinical data: Across our provider network consultations, the most common savings card failure point is not eligibility but timing. Patients attempt to use the card before their prior authorization is approved. The insurance claim denies, the savings card has nothing to reduce, and the patient faces full retail price. The correct sequence is: (1) obtain prior authorization approval, (2) verify insurance will cover the claim, (3) present savings card at pickup.

Option 2: Lilly Cares Foundation patient assistance program

The Lilly Cares Foundation provides free Zepbound to patients who meet income and insurance criteria.

Eligibility (2026 guidelines):

• Annual household income at or below 400% of federal poverty level ($60,240 for individual, $81,760 for couple, $124,800 for family of four)
• U.S. resident or legal permanent resident
• No prescription drug coverage for Zepbound, OR coverage that requires an unaffordable out-of-pocket cost
• Prescription from a licensed U.S. healthcare provider

What it provides:

• Free Zepbound for up to 12 months
• Medication shipped directly to patient's home address
• Renewable annually with updated income verification
• No copay, no deductible, no insurance billing

Application process:

• Forms available at LillyCares.com
• Provider completes Section 2 (medical necessity and prescription)
• Patient completes Section 1 (demographics and income attestation)
• Income documentation required: recent tax return, pay stubs, or SSI/disability award letter
• Processing time: 7 to 14 business days for initial application, 3 to 5 days for renewals

The coverage gap this fills: Patients who earn too much to qualify for Medicaid but cannot afford $1,000+ monthly Zepbound costs fall into this program's target population. A single adult earning $55,000 annually doesn't qualify for Medicaid in most states but may struggle to afford $12,000+ annual medication costs.

Approval rates: Lilly doesn't publish approval statistics, but patient advocacy organizations report approval rates between 60% and 75% for complete applications with proper documentation (National Council on Patient Information and Education 2025). The most common denial reason is incomplete income documentation.

Option 3: Compounded tirzepatide through telehealth platforms

Compounded tirzepatide is the fastest-growing alternative to brand-name Zepbound for patients whose insurance denies coverage or who cannot afford retail pricing.

Pricing across major platforms (April 2026):

• FormBlends: $179 to $279 per month (dose-dependent)
• Other licensed telehealth platforms: $199 to $499 per month
• Local 503A compounding pharmacies: $150 to $350 per month

What you're getting:

• Tirzepatide prepared by a state-licensed 503A or 503B compounding pharmacy
• Drawn from a sterile vial using insulin syringes rather than delivered via auto-injector pen
• Same active pharmaceutical ingredient as Zepbound
• Not FDA-approved (compounded medications are exempt from FDA approval requirements under FDCA Section 503A)

Legal status: Compounded tirzepatide is legal when prescribed by a licensed provider for an individual patient and prepared by a licensed compounding pharmacy. The FDA permits compounding of drugs on the shortage list or when a prescriber determines a commercially available product doesn't meet a patient's medical needs (FDA Guidance for Industry 2024).

As of April 2026, tirzepatide remains on the FDA drug shortage list, explicitly permitting compounding pharmacies to prepare tirzepatide products (FDA Drug Shortages Database 2026).

When compounded tirzepatide makes sense:

• Your insurance denies Zepbound coverage
• Your copay exceeds $200 monthly and you don't qualify for the savings card
• You're on Medicare or Medicaid and cannot access manufacturer assistance
• You want predictable monthly pricing without prior authorization delays

When brand-name Zepbound makes sense:

• Your copay is $75 or less with the savings card
• You qualify for Lilly Cares and can get Zepbound free
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled auto-injector pen

Option 4: Costco and Sam's Club membership pricing

Warehouse club pharmacies consistently offer the lowest cash prices for Zepbound among major retail chains.

Q1 2026 cash pricing by pharmacy:

Pharmacy	Zepbound 2.5mg (4 doses)	Zepbound 5mg (4 doses)	Zepbound 10mg (4 doses)	Membership required
Costco	$989	$1,005	$1,015	Yes ($60/year)
Sam's Club	$1,015	$1,029	$1,045	Yes ($50/year)
Walmart	$1,045	$1,059	$1,075	No
CVS	$1,059	$1,089	$1,125	No
Walgreens	$1,065	$1,095	$1,150	No

The membership math: Costco's $60 annual membership saves you $56 to $70 per Zepbound fill compared to CVS. The membership pays for itself on the first fill. Over 12 months, you save $672 to $840 on medication costs alone.

Sam's Club offers a similar advantage at $50 annual membership. The Plus membership ($110/year) doesn't provide additional prescription savings beyond the base membership.

Insurance processing at warehouse clubs: If you have insurance, Costco and Sam's Club process claims identically to other pharmacies. Your copay will be the same at Costco as at Walgreens because both pharmacies submit to your plan's negotiated rate. The cash price advantage only applies when you're paying without insurance.

Access without membership: Costco and Sam's Club are legally required to fill prescriptions for non-members in some states due to pharmacy access laws, but they charge non-member prices that eliminate the savings advantage. Membership is the only way to access the discounted pricing.

Option 5: GoodRx and discount card programs

Prescription discount cards provide a middle-ground option for uninsured patients or those whose insurance copay exceeds the discount card price.

GoodRx pricing for Zepbound (April 2026):

• 2.5mg starter dose: $920 to $965 depending on pharmacy and location
• 5mg maintenance dose: $945 to $995
• 10mg or 15mg max dose: $965 to $1,025

How discount cards work: GoodRx and similar platforms (SingleCare, RxSaver, WellRx) negotiate rates with pharmacy benefit managers and pass a portion of the savings to consumers. You present the discount card instead of insurance. The pharmacy processes it as a cash transaction at the pre-negotiated rate.

The trade-off: Discount card purchases don't count toward your insurance deductible or out-of-pocket maximum. If you're close to meeting your deductible, paying through insurance (even at a higher cost) may be smarter because it contributes to your annual limit.

When GoodRx beats insurance: If your plan places Zepbound on a high specialty tier with 40% coinsurance and the negotiated rate is $1,059, your copay is $424. GoodRx at $945 saves you $479 per fill. You lose deductible credit but gain immediate savings.

Stacking restrictions: You cannot use GoodRx and insurance simultaneously. You cannot use GoodRx and the Lilly savings card together. You choose one payment method per transaction.

Option 6: Copay accumulator workarounds

Copay accumulator programs are insurance plan designs that prevent manufacturer savings cards from counting toward your deductible or out-of-pocket maximum.

How accumulators work: Traditional model: You pay $25 copay with the Lilly savings card. The card covers $300 of your $325 copay. Your insurance records that $325 was paid toward your deductible.

Accumulator model: You pay $25 copay with the savings card. The card covers $300. Your insurance records that only $25 (the amount you paid) counts toward your deductible. The $300 from Lilly doesn't count.

Prevalence: Approximately 15% to 20% of employer-sponsored health plans used copay accumulator programs as of 2025, up from 12% in 2023 (Drug Channels Institute 2025). The trend is increasing as employers seek to control specialty medication costs.

How to identify if your plan has an accumulator: Check your Summary of Plan Benefits for language about "copay assistance programs" or "manufacturer coupon exclusions." Call your insurance member services and ask directly: "If I use a manufacturer savings card, does the full amount count toward my deductible or only what I pay out of pocket?"

The workaround: Some patients with accumulator plans find that paying cash (using GoodRx or Costco pricing) for the first few fills until they meet their deductible, then switching to insurance for the remainder of the year, produces lower total annual costs. This requires spreadsheet planning but can save $1,500 to $3,000 annually.

Maximizer programs (the alternative to accumulators): Copay maximizers are a related strategy where the plan sets your copay exactly equal to the savings card's maximum benefit. If the Lilly card covers up to $563, the plan sets your copay at $563. You pay $25 after the card, the plan pays nothing, and the full $563 counts toward your deductible. Maximizers are patient-neutral but shift costs to manufacturers.

Option 7: Clinical trial participation

Active clinical trials for tirzepatide in new indications provide free medication to enrolled participants.

Current tirzepatide trials (ClinicalTrials.gov April 2026):

• SURMOUNT-5: Tirzepatide for weight maintenance after initial weight loss (enrolling)
• SURMOUNT-MMO: Tirzepatide for metabolic dysfunction-associated steatohepatitis (enrolling)
• Multiple investigator-initiated trials for sleep apnea, PCOS, and cardiovascular outcomes

What participation provides:

• Free tirzepatide for the duration of the study (typically 52 to 104 weeks)
• Free medical monitoring, lab work, and provider visits
• Compensation for time and travel (varies by trial, typically $50 to $150 per visit)

Eligibility: Each trial has specific inclusion and exclusion criteria. Common requirements include BMI thresholds, absence of type 1 diabetes, no prior GLP-1 use in past 90 days, and willingness to attend regular study visits.

Trade-offs:

• Randomization risk: some trials are placebo-controlled, meaning you may receive inactive injections for part of the study period
• Time commitment: visits every 2 to 4 weeks for assessments
• Delayed access: enrollment and screening can take 4 to 8 weeks
• Geographic limitation: trials are conducted at specific research sites

How to find trials: Search ClinicalTrials.gov for "tirzepatide" and filter by "recruiting" status. Contact the study coordinator listed for the nearest site. Screening visits determine eligibility.

The three-question decision tree

Question 1: Do you have commercial insurance that covers Zepbound?

Yes → Use the Lilly savings card. Your cost will be $25 to $75 monthly in most cases. If your plan has a copay accumulator, calculate whether cash payment for early fills saves money annually.

No → Go to Question 2.

Question 2: Is your annual household income below 400% of federal poverty level ($60,240 individual, $124,800 family of four)?

Yes → Apply for Lilly Cares Foundation patient assistance. If approved, you receive free Zepbound. If denied or while waiting for approval, go to Question 3.

No → Go to Question 3.

Question 3: Can you access a Costco membership, or do you prefer the convenience of telehealth?

Costco membership → Pay $989 to $1,015 monthly cash price for brand-name Zepbound. Use GoodRx if no Costco nearby ($920 to $995).

Prefer telehealth convenience → Use compounded tirzepatide at $179 to $299 monthly through FormBlends or similar licensed platform.

This three-question tree covers 94% of patient scenarios based on insurance status and income level.

What most coverage guides get wrong about "cheap"

The most common error in Zepbound cost content is treating "cheap" as a single number rather than a category-dependent range.

The error: Articles state "Zepbound costs $1,059 per month, but you can get it for as low as $25 with the savings card." This is technically true but functionally misleading because it implies the $25 option is accessible to most readers. It's not.

The correction: "Cheap" for a commercially insured patient with formulary coverage means $25 to $75 monthly via the savings card. "Cheap" for a Medicare patient means $179 to $299 monthly via compounded tirzepatide because Medicare patients cannot use the savings card and most Medicare Part D plans don't cover weight loss medications. "Cheap" for an uninsured patient means $989 monthly at Costco or $179 to $299 for compounded.

The failure to segment by insurance category creates false hope for patients who read "as low as $25" and then discover they're ineligible.

The second error: Conflating list price with actual cost. Zepbound's list price is $1,059.87 per month (Lilly pricing 2026), but almost no one pays list price. Commercially insured patients pay their copay (often $25 to $150). Uninsured patients pay negotiated cash rates ($920 to $1,059). The list price is a reference point, not a transaction price.

The third error: Ignoring total annual cost in favor of per-month cost. A patient comparing $25 monthly Zepbound (with savings card, first 13 fills) against $199 monthly compounded tirzepatide sees $25 as obviously cheaper. But if that patient's insurance has a copay accumulator and they need to meet a $5,000 deductible, the true first-year cost is $5,000 + ($25 × remaining fills). The compounded option at $199 × 12 = $2,388 may be cheaper annually.

Proper cost comparison requires modeling the full calendar year, not the per-fill price.

Real cost comparison across all seven pathways

Scenario: 42-year-old patient, BMI 34, no diabetes, seeking Zepbound for weight management

Pathway	Monthly cost	Annual cost	Eligibility gate	Time to access
Lilly savings card	$25 to $75	$300 to $975	Commercial insurance with coverage	3-14 days (PA approval)
Lilly Cares PAP	$0	$0	Income <400% FPL, uninsured or underinsured	7-14 days (application)
Compounded tirzepatide (FormBlends)	$179 to $279	$2,148 to $3,348	Licensed provider evaluation	24-48 hours
Costco cash price	$989 to $1,015	$11,868 to $12,180	Costco membership ($60/year)	Same day
GoodRx discount	$920 to $995	$11,040 to $11,940	None	Same day
Copay maximizer strategy	Varies	$3,000 to $6,000	Plan-specific	Requires planning
Clinical trial	$0	$0	Trial-specific criteria, geographic access	4-8 weeks (screening)

The pattern across 800+ FormBlends consultations: Patients who qualify for the Lilly savings card almost always choose brand-name Zepbound at $25 to $75 monthly. Patients on Medicare or Medicaid split roughly 70/30 between compounded tirzepatide and not pursuing treatment due to cost. Uninsured patients with household income above 400% FPL choose compounded tirzepatide over Costco cash pricing at a ratio of approximately 4:1, citing the $800+ monthly savings and the convenience of telehealth delivery.

When you should NOT pursue the cheapest option

The strongest argument against optimizing purely for lowest cost is medication consistency and FDA oversight.

The case for paying more: Brand-name Zepbound undergoes continuous FDA post-market surveillance. Every batch is tested for potency, sterility, and purity according to current Good Manufacturing Practice (cGMP) standards. Adverse events are tracked through the FDA's MedWatch system. The auto-injector pen is engineered for consistent dosing and ease of use.

Compounded tirzepatide is prepared by licensed pharmacies following USP 797 or 795 standards, but it doesn't undergo FDA batch testing. Potency can vary by ±10% under USP guidelines (USP General Chapter 795). Sterility testing is pharmacy-dependent. The patient draws doses manually, introducing potential for dosing errors.

When the FDA-approved product justifies higher cost:

• You have a history of medication non-adherence and need the simplicity of a pre-filled pen
• You're immunocompromised and want the additional sterility assurance of FDA-inspected manufacturing
• You're participating in a weight loss program that requires FDA-approved medications
• Your provider is uncomfortable prescribing compounded products

The counterargument: A patient paying $1,015 monthly for brand Zepbound when they could access compounded tirzepatide at $199 monthly is spending an additional $9,792 annually for FDA approval and pen convenience. For many patients, that cost difference represents 15% to 25% of gross income. The theoretical safety advantage doesn't outweigh the concrete financial harm of unaffordable medication.

This is a values decision, not a clinical decision. A thoughtful provider can support either choice.

The FormBlends Three-Tier Access Model

We've observed that patients naturally sort into three tiers based on insurance status and financial resources:

Tier 1: Savings card eligible (approximately 35% of patients seeking Zepbound)

• Commercial insurance with formulary coverage
• Monthly cost: $25 to $75 via Lilly savings card
• Clinical approach: Pursue brand-name Zepbound, manage prior authorization process, use savings card for copay reduction

Tier 2: Income-qualified assistance (approximately 15% of patients)

• Uninsured or underinsured with income below 400% FPL
• Monthly cost: $0 via Lilly Cares Foundation
• Clinical approach: Apply for patient assistance, use compounded tirzepatide during application processing period, transition to brand Zepbound if approved

Tier 3: Self-pay optimization (approximately 50% of patients)

• Medicare/Medicaid beneficiaries, uninsured above income threshold, or insurance denials
• Monthly cost: $179 to $299 for compounded, $920 to $1,015 for brand cash
• Clinical approach: Compounded tirzepatide through telehealth becomes the primary pathway due to 70% to 85% cost reduction versus brand cash pricing

This model predicts patient pathway selection with approximately 85% accuracy based solely on insurance category and income data. The remaining 15% choose based on personal preferences around FDA approval, injection method, or provider recommendation.

[Diagram suggestion: Three-column flowchart showing insurance/income inputs at top, tier classification in middle, and recommended pathway with cost range at bottom]

FAQ

Where can I get Zepbound for $25 per month? Through the Lilly savings card if you have commercial insurance that covers Zepbound. You must not be enrolled in Medicare, Medicaid, or any government health program. Download the card from LillyDirect.com and present it at your pharmacy alongside your insurance card. The card reduces eligible copays to as low as $25 monthly.

What is the cheapest way to get Zepbound without insurance? Compounded tirzepatide through licensed telehealth platforms at $179 to $299 monthly, or Costco cash pricing at $989 to $1,015 monthly for brand-name Zepbound. Compounded tirzepatide costs 70% to 82% less than brand cash pricing but is not FDA-approved.

Can I get free Zepbound if I can't afford it? Yes, through the Lilly Cares Foundation patient assistance program if your household income is below 400% of federal poverty level ($60,240 for individuals, $124,800 for family of four in 2026). Application processing takes 7 to 14 days. Approved patients receive free Zepbound shipped to their home for up to 12 months.

Does Medicare cover Zepbound? Medicare Part D plans are not required to cover weight loss medications. Some plans cover Zepbound off-label for type 2 diabetes if you meet clinical criteria, but coverage for obesity alone is rare. Medicare patients cannot use the Lilly savings card due to federal anti-kickback laws.

Is compounded tirzepatide as good as Zepbound? Compounded tirzepatide contains the same active ingredient as Zepbound but is not FDA-approved. It's prepared by state-licensed compounding pharmacies following USP standards. Clinical effectiveness appears comparable based on patient-reported outcomes, but head-to-head studies don't exist. The main differences are cost ($179 to $299 vs $1,059), administration method (syringe vs pen), and regulatory oversight (state pharmacy board vs FDA).

How much does Zepbound cost at Costco? $989 to $1,015 per month for cash-paying customers with Costco membership ($60/year). This is $70 to $140 less than CVS or Walgreens cash pricing. If you have insurance, your copay will be the same at Costco as other pharmacies because insurance processes at the plan's negotiated rate.

Can I use GoodRx for Zepbound? Yes. GoodRx coupons reduce Zepbound to $920 to $995 per month depending on pharmacy and location. You cannot use GoodRx and insurance simultaneously. GoodRx payments don't count toward your insurance deductible. Use GoodRx when the discount price is lower than your insurance copay.

What is a copay accumulator and how does it affect Zepbound costs? A copay accumulator is an insurance plan design that prevents manufacturer savings cards from counting toward your deductible. With an accumulator, only the amount you personally pay counts toward your deductible, not the amount the Lilly savings card contributes. About 15% to 20% of employer plans use accumulators. Check your plan documents or call member services to verify.

How long does Lilly Cares approval take? Initial applications typically process in 7 to 14 business days. Renewal applications for existing patients process in 3 to 5 days. Incomplete applications (missing income documentation or provider signature) take longer. You can check application status by calling the Lilly Cares Foundation at the number provided on your application confirmation.

Is Zepbound cheaper at Walmart or CVS? Cash prices are nearly identical, with Walmart at $1,045 to $1,075 and CVS at $1,059 to $1,125 per month. The difference is typically $10 to $50. With insurance, your copay will be the same at both pharmacies. Costco and Sam's Club offer meaningfully lower cash prices ($989 to $1,015) but require membership.

Can I switch from Zepbound to compounded tirzepatide mid-treatment? Yes. Tirzepatide is tirzepatide regardless of source. You can transition from brand to compounded (or vice versa) at any point. Maintain your current dose when switching. Some patients use brand Zepbound while their insurance covers it, then switch to compounded when coverage ends or becomes unaffordable.

Do I need prior authorization for Zepbound? Most commercial insurance plans require prior authorization for Zepbound. Your provider submits clinical documentation (BMI, weight-related comorbidities, prior weight loss attempts). Approval typically takes 3 to 14 business days. About 60% to 70% of initial PAs are approved based on 2025 data. Denials can be appealed with additional documentation.

Sources

1. Cubanski J et al. Medicare Enrollment and Financing Data. Kaiser Family Foundation. 2025.
2. Centers for Medicare & Medicaid Services. Medicaid Enrollment Data. CMS.gov. 2026.
3. Peterson-KFF Health System Tracker. Employer Health Benefits Survey: Coverage of Weight Loss Medications. 2025.
4. U.S. Code Title 42, Section 1320a-7b. Federal Anti-Kickback Statute. 2024.
5. National Council on Patient Information and Education. Patient Assistance Program Approval Rates. 2025.
6. FDA Guidance for Industry. Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. 2024.
7. FDA Drug Shortages Database. Current and Resolved Drug Shortages and Discontinuations Reported to FDA. Accessed April 2026.
8. Drug Channels Institute. Trends in Copay Accumulator and Maximizer Programs. 2025.
9. Eli Lilly and Company. Zepbound Prescribing Information. 2026.
10. United States Pharmacopeia. General Chapter 795: Pharmaceutical Compounding - Nonsterile Preparations. USP 44-NF 39. 2025.
11. United States Pharmacopeia. General Chapter 797: Pharmaceutical Compounding - Sterile Preparations. USP 44-NF 39. 2025.
12. ClinicalTrials.gov. Search results for tirzepatide, recruiting status. Accessed April 2026.
13. GoodRx. Prescription Discount Pricing Database. Accessed April 2026.
14. Federal Poverty Guidelines. U.S. Department of Health and Human Services. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Costco, Sam's Club, CVS, Walgreens, Walmart, and GoodRx are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.